These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11770983)

  • 1. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials.
    Townsend HG; Penner SJ; Watts TC; Cook A; Bogdan J; Haines DM; Griffin S; Chambers T; Holland RE; Whitaker-Dowling P; Youngner JS; Sebring RW
    Equine Vet J; 2001 Nov; 33(7):637-43. PubMed ID: 11770983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression.
    Lunn DP; Hussey S; Sebing R; Rushlow KE; Radecki SV; Whitaker-Dowling P; Youngner JS; Chambers TM; Holland RE; Horohov DW
    J Am Vet Med Assoc; 2001 Mar; 218(6):900-6. PubMed ID: 11294315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge.
    Chambers TM; Holland RE; Tudor LR; Townsend HG; Cook A; Bogdan J; Lunn DP; Hussey S; Whitaker-Dowling P; Youngner JS; Sebring RW; Penner SJ; Stiegler GL
    Equine Vet J; 2001 Nov; 33(7):630-6. PubMed ID: 11770982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza.
    Tabynov K; Kydyrbayev Zh; Ryskeldinova Sh; Assanzhanova N; Sansyzbay A
    Vaccine; 2014 May; 32(25):2965-71. PubMed ID: 24726250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a novel cold-adapted modified-live equine influenza virus vaccine.
    Tabynov K; Kydyrbayev Z; Ryskeldinova S; Assanzhanova N; Kozhamkulov Y; Inkarbekov D; Sansyzbay A
    Aust Vet J; 2014 Nov; 92(11):450-7. PubMed ID: 25348146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.
    Chambers TM; Quinlivan M; Sturgill T; Cullinane A; Horohov DW; Zamarin D; Arkins S; García-Sastre A; Palese P
    Equine Vet J; 2009 Jan; 41(1):87-92. PubMed ID: 19301588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination.
    Soboll G; Hussey SB; Minke JM; Landolt GA; Hunter JS; Jagannatha S; Lunn DP
    Vet Immunol Immunopathol; 2010 May; 135(1-2):100-107. PubMed ID: 20018384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivation and characterization of a live attenuated equine influenza vaccine virus.
    Youngner JS; Whitaker-Dowling P; Chambers TM; Rushlow KE; Sebring R
    Am J Vet Res; 2001 Aug; 62(8):1290-4. PubMed ID: 11497453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
    Heldens JG; Pouwels HG; van Loon AA
    Vet J; 2004 Mar; 167(2):150-7. PubMed ID: 14975389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.
    Nelson KM; Schram BR; McGregor MW; Sheoran AS; Olsen CW; Lunn DP
    Vaccine; 1998 Aug; 16(13):1306-13. PubMed ID: 9682395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a non-updated, Matrix-C-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge.
    Pouwels HG; Van de Zande SM; Horspool LJ; Hoeijmakers MJ
    Vet Rec; 2014 Jun; 174(25):633. PubMed ID: 24795071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of equine influenza virus shedding and infectivity in immunised horses after experimental infection with EIV A/eq2/Richmond/1/07.
    Paillot R; Prowse L; Montesso F; Stewart B; Jordon L; Newton JR; Gilkerson JR
    Vet Microbiol; 2013 Sep; 166(1-2):22-34. PubMed ID: 23769636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding.
    Paillot R; Prowse L; Donald C; Medcalf E; Montesso F; Bryant N; Watson J; Jeggo M; Elton D; Newton R; Trail P; Barnes H
    Vet Immunol Immunopathol; 2010 Aug; 136(3-4):272-83. PubMed ID: 20400185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.
    Crouch CF; Daly J; Hannant D; Wilkins J; Francis MJ
    Vaccine; 2004 Dec; 23(3):418-25. PubMed ID: 15530689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cold-adapted vaccine-strain influenza virus using two commercial assays.
    Adam EN; Morley PS; Chmielewski KE; Carman J; Gonzales G
    Equine Vet J; 2002 Jul; 34(4):400-4. PubMed ID: 12117114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom.
    Edlund Toulemonde C; Daly J; Sindle T; Guigal PM; Audonnet JC; Minke JM
    Vet Rec; 2005 Mar; 156(12):367-71. PubMed ID: 15816180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.
    Paillot R; Prowse L; Montesso F; Huang CM; Barnes H; Escala J
    Vet Microbiol; 2013 Mar; 162(2-4):396-407. PubMed ID: 23146168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses.
    Crouch CF; Daly J; Henley W; Hannant D; Wilkins J; Francis MJ
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):345-55. PubMed ID: 16098611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines.
    Mumford JA; Jessett DM; Rollinson EA; Hannant D; Draper ME
    Vet Rec; 1994 Feb; 134(7):158-62. PubMed ID: 8160328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.
    Minke JM; Toulemonde CE; Coupier H; Guigal PM; Dinic S; Sindle T; Jessett D; Black L; Bublot M; Pardo MC; Audonnet JC
    Am J Vet Res; 2007 Feb; 68(2):213-9. PubMed ID: 17269889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.